A Phase 2 interventional study of EPO in Myocardial Infarction, sponsored by University Hospital, Angers. Completed at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-01-31.
Sponsored by University Hospital, Angers · Phase 2, Interventional, and Treatment
EPOMI is a randomized, open-label, parallel phase II clinical study that will evaluate the effects of a single erythropoietin administration on infarct size and cardiac remodeling in patients with acute myocardial infarction. Eligible patients will be randomly assigned to receive conventional therapy and single infusion of 1000U/kg of epoetin beta or conventional therapy alone. Infarct size and cardiac remodeling parameters will be assessed by cardiac magnetic resonance imaging (MRI) within 3-7 days of the randomization and repeated 3 months later.
2,744 studies on the registry are indexed under Myocardial Infarction; 418 are open to participants now.
This study's enrollment of 110 is below the median of 148 across 1,595 interventional studies indexed under Myocardial Infarction.
Browse Myocardial Infarction studies →University Hospital, Angers is the lead sponsor of 464 studies on the registry; 116 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: EPO
Single Injection of 1000 U/kg Erythropoietin beta IV immediately after primary PCI
Changes in infarct size as assessed by magnetic resonance imaging 3 months after administration of study medication
Time frame: within 3-7 days of administration of study medication
End-systolic volume, end-diastolic volume, ejection fraction
Time frame: within 3-7 days of administration of study medication, and 3 months later
Changes in hemoglobin, platelets, reticulocytes blood count
Time frame: during the first 10 days following study medication administration
Occurrence of major cardiac event or venous thrombotic events
Time frame: within 12 months following administration of study medication
This study is completed, as verified in Jan 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Angers